Ian Webster has served as our Interim Chief Financial Officer since June 2025 and previously served as our Director of Finance since 2019.

filing / Mar 19, 2026 / receipt

Webster was appointed as our Interim Chief Financial Officer effective June 18, 2025. (4) Dr. Muralidhar retired from the board on October 21, 2025.

filing / Mar 19, 2026 / receipt

In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or E.U.

filing / Mar 19, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any of our products for which we receive marketing approval.

filing / Mar 19, 2026 / receipt

The Company extended its office lease contract in 2025, which resulted in a re-measurement of the right of use asset and lease liability of £ 0.5 million.

filing / Mar 19, 2026 / receipt

and cannot be predicted with confidence, such as the emergence, severity and spread of new variants of a disease, the duration of a pandemic and any outbreak of future variants, the potential imposition of travel restrictions and actions to contain a pandemic and any future outbreaks, such as social distancing and quarantines or lock-downs in the United Kingdom, the United States and other countries, business closure

filing / Mar 19, 2026 / receipt

Hugh Griffith | 57 | Chief Executive Officer and Director

filing / Mar 19, 2026 / receipt

Jeffrey Bloss | 69 | Chief Medical Officer

filing / Mar 19, 2026 / receipt

David Harrison | 66 | Head of Translational Medicine

filing / Mar 19, 2026 / receipt

Ian Webster | 45 | Interim Chief Financial Officer

filing / Mar 19, 2026 / receipt

Theresa Bruce | 61 | Chief Operating Officer

filing / Mar 19, 2026 / receipt

Andrew Kay | 70 | Non-Executive Director and Chairman

filing / Mar 19, 2026 / receipt